A share price of Sera Prognostics Inc [SERA] is currently trading at $4.09, up 106.57%. An important factor to consider is whether the stock is rising or falling in short-term value. The SERA shares have gain 113.02% over the last week, with a monthly amount glided 147.88%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sera Prognostics Inc [NASDAQ: SERA] stock has seen the most recent analyst activity on March 30, 2022, when Citigroup downgraded its rating to a Neutral and also revised its price target to $4 from $18. Previously, Oppenheimer started tracking the stock with Outperform rating on November 19, 2021, and set its price target to $19.
Sera Prognostics Inc experienced fluctuations in its stock price throughout the past year between $1.37 and $9.13. Sera Prognostics Inc [NASDAQ: SERA] shares were valued at $4.09 at the most recent close of the market.
Analyzing the SERA fundamentals
Gross Profit Margin for this corporation currently stands at 0.09% with Operating Profit Margin at -319.9%, Pretax Profit Margin comes in at -286.85%, and Net Profit Margin reading is -286.85%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.51 and Total Capital is -0.39. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.70 points at the first support level, and at 1.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.78, and for the 2nd resistance point, it is at 5.48.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Sera Prognostics Inc [NASDAQ:SERA] is 2.02. On the other hand, the Quick Ratio is 2.02, and the Cash Ratio is 0.22. Considering the valuation of this stock, the price to sales ratio is 1284.00, the price to book ratio is 1.63.
Transactions by insiders
Recent insider trading involved Jackson Benjamin, General Counsel, that happened on Jun 10 ’25 when 965.0 shares were sold. Chief Scientific Officer, Boniface John J. completed a deal on Jun 10 ’25 to sell 1439.0 shares. Meanwhile, Officer Lindgardt Zhenya bought 3344.0 shares on Jun 10 ’25.
